Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11284980 | 1.00 | PYGL (0.50) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL6489385 | 1.00 | PYGL (0.50) | PYGLKDM4EGMNNLMNAMAPT | |
| Phosphoric Acid SCHEMBL30522657 | 0.93 | PYGL (0.45) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL3842183 | 0.86 | PYGL (0.37) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL16620205 | 0.79 | UMPS (0.44) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL4359388 | 0.78 | FBP1 (0.53) | SMN1; SMN2 | |
| SCHEMBL8152014 | 0.76 | PYGL (0.55) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL7033031 | 0.76 | PYGL (0.55) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL6785146 | 0.74 | MAPT (0.50) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL4666736 | 0.74 | MAPT (0.50) | PYGLKDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0004261-B1 | IMIDAZOLE DERIVATIVES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-04-28 | — | — | EP | claimed |
| CN-111386340-B | Detergent compositions comprising polypeptide variants | 宝洁公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-109477083-B | Thermostable metagenomic carbonic anhydrases and uses thereof | 诺维信公司 | 2023-06-06 | — | — | CN | disclosed |
| US-10472677-B2 | Translational dysfunction based therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-1971690-B1 | TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS | TRANSLATIONAL THERAPEUTICS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2015050957-A2 | TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS | TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20140213632-A1 | HCV Combination Therapy | STELLA APS (DK) | 2014-07-31 | — | — | US | disclosed |
| US-20140127159-A1 | HCV Combination Therapy | STELLA APS (DK) | 2014-05-08 | — | — | US | disclosed |
| EP-2726611-A1 | HCV COMBINATION THERAPY | Stella ApS (DK) | 2014-05-07 | — | — | EP | disclosed |
| EP-2726610-A1 | HCV COMBINATION THERAPY | Stella ApS (DK) | 2014-05-07 | — | — | EP | disclosed |
| EP-0724587-B8 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-0724587-A4 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | BURNS BARRY (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0724587-A1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | Burns, Barry (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995009175-A1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | BURNS BARRY (US) | 1995-04-06 | — | — | WO | disclosed |
| EP-0542867-A4 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | — | 1993-07-28 | — | — | EP | disclosed |
| EP-0542867-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA, INC. (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0004261-A2 | Imidazole derivatives, method for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-10-03 | — | — | EP | disclosed |
| US-4115641-A | CARDIAC AND CIRCULATORY-DYNAMIC PROPERTIES, ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4115641-A | CARDIAC AND CIRCULATORY-DYNAMIC PROPERTIES, ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4115641-A | CARDIAC AND CIRCULATORY-DYNAMIC PROPERTIES, ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127159-A1 | HCV Combination Therapy | HAVCR2, EIF2AK2, TIMP3 | PYGL 1025/4885KDM4E 1506/4885GMNN 4330/4885 |
| US-20140213632-A1 | HCV Combination Therapy | HAVCR2, EIF2AK2, ZC3HAV1 | PYGL 1331/4885KDM4E 3152/4885GMNN 3467/4885 |
| US-10472677-B2 | Translational dysfunction based therapeutics | EIF4EBP1, EIF4E, EIF4A1 | PYGL 2504/4885KDM4E 1464/4885GMNN 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.